Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease

Prostaglandins and Other Lipid Mediators

Volumn 80, Issue 3-4, 2006, Pages 175-182

  Blardi, Patrizia ^a   de Lalla, Arianna ^a   Pieragalli, Daniela ^a   De Franco, Vincenzo ^a   Meini, Simone ^a   Ceccatelli, Linda ^a   Auteri, Alberto ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Asymmetric dimethylarginine; Iloprost; Peripheral arterial occlusive disease; Serotonin

Indexed keywords

ILOPROST; N(G),N(G) DIMETHYLARGININE; SEROTONIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SEROTONIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE; TITRIMETRY; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ARGININE; ARTERIAL OCCLUSIVE DISEASES; BLOOD PLATELETS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FEMALE; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; SEROTONIN; TREATMENT OUTCOME;

EID: 33747828441     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2006.06.005     Document Type: Article

References (50)

1. Loosemore T.M., Chalmers T.C., and Dormandy J.A. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 13 (1994) 133-142
2. Staben P., and Albring M. Treatment of patients with peripheral arterial occlusive disease Fontaine stages III and IV with intravenous iloprost: an open study in 900 patients. Prostaglandins Leukot Essent Fatty Acids 54 (1996) 327-333
3. Beischer W., Dembski J.C., Gruss J.D., et al. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. Vasa 27 1 (1998) 15-19
4. Mazzone A., Vezzoli M., Ottini E., et al. A new method of iloprost administration without a peristaltic pump. Curr Ther Res 61 (2000) 452-459
5. Grant S.M., and Goa K.L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs 43 (1992) 889-924
6. Ceriello A., Sardina M., Motz E., et al. Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III. Int J Angiol 7 (1998) 28-33
7. Minnucci A., and Agostinis M. Iloprost: a new simplified therapeutical regimen in patients with peripheral occlusive arterial disease at Leriche-Fontaine stages III and IV. Int Med 7 (1999) 87-89
8. Meini S., De Franco V., and Auteri A. Short-term and long-term effects of 1-week treatment with intravenous iloprost in critical limb ischaemia patients (Leriche-Fontaine stages III and IV). Int Angiol 24 1 (2005) 64-69
9. Czeslick E.G., Simm S., Grond R.E., et al. Inhibition of intracellular tumor necrosis factor (TNF)-α and IL-6 production in human monocytes by iloprost. Eur J Clin Invest 33 (2003) 1013-1017
10. Debey S., Kirchrath L., Schror K., and Meyer-Kirchrath J. Iloprost down-regulates the expression of the growth regulatory gene Cur61 in human vascular smooth muscle cells. Eur J Pharmacol 474 (2003) 161-164
11. Pola R., Gaetani E., Flex A., et al. Comparative analysis of the in vivo giogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator activated receptors. J Mol Cell Cardiol 36 (2004) 363-370
12. Bozkurt A.K. Alpha-tocopherol and iloprost attenuate reperfusion injury in skeletal muscle ischemia/reperfusion injury. J Cardiovasc Surg 43 (2002) 693-696
13. Tran C.T.L., Leiper J.M., and Vallance P. The DDAH/ADMA/NOS pathway. Atheroscl Suppl 4 (2003) 33-40
14. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
15. Stühlinger M.C., Oka R.K., Graf E.E., et al. Endothelial dysfunction induced by hyperhomocysteinemia. Role of asymmetric dimethylargine. Circulation 108 (2003) 933-938
16. Boger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59 (2003) 824-833
17. Zoccali C., Bode-Böger S.M., and Mallamaci F. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358 (2001) 2113-2117
18. Zoccali C., Mallamaci F., and Maas R. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62 (2002) 339-345
19. Valkonen V.P., Päivä H., and Salonen J.T. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
20. Böger R.H., Bode-Böger S.M., Thiele W., et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 (1997) 2068-2074
21. Surdacki A., Nowicki M., and Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
22. Böger R.H., Bode-Böger S.M., Thiele W., et al. Restoring vascular NO formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 32 (1998) 1336-1344
23. Usui M., Matsuoka H., and Miyazaki H. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62 (1998) 2425-2430
24. Abbasi F., Asagmi T., and Cooke J.P. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
25. Golino P., Crea F., and Willerson J. How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance. Ital Heart J 3 (2002) 220-225
26. Willerson J.T., Golino P., and Edit J. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 80 (1989) 198-205
27. Ashton J.H., Benedict C.R., and Fitzgerald C. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 73 (1986) 572-578
28. Kawano H., Tsuji H., and Nishimura H. Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97 (2001) 1697-1702
29. Nemecek G.M., Coughlin S.R., and Handley D.A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 83 (1986) 674-678
30. Pakala R., Willerson J.T., and Benedict C.R. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 90 (1994) 1919-1926
31. Ito T., Ikeda U., and Shimpo M. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation 102 (2000) 2522-2527
32. Seino Y., Ikeda U., and Yamamoto K. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6 (1994) 87-91
33. Erren M., Reinecke H., and Junker R. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19 (1999) 2355-2363
34. Golino P., Piscione F., and Willerson J.T. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Eng J Med 324 (1991) 641-648
35. McFadden E.P., Clarke J.G., and Davies G.J. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Eng J Med 324 (1991) 648-654
36. Golino P., Piscione F., and Benedict C.R. Local effect of serotonin released during coronary angioplasty. N Eng J Med 30 (1994) 523-528
37. Vikenes K., Farstad M., and Nordrehaug J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation 100 (1999) 483-489
38. Blardi P., Palazzuoli A., de Lalla A., and Auteri A. Variations of peripheral markers of serotoninergic system in selected vascular patients. Nutr Metab Cardiovasc Dis 16 (2006) 210-214
39. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anayt Biochem 303 (2002) 131-137
40. Tagari P.C., Boullin D.J., and Davies C.L. Simplified determination of serotonin in plasma by liquid chromatography with electrochemical detection. Clin Chem 30 (1984) 131-135
41. Mustard F., Perry D.W., Ardlie N.G., et al. Preparation of suspensions of washed platelets from humans. Br J Haematol 22 (1972) 193-204
42. Mc Carty M.F. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine-an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction. Med Hypotheses 63 (2004) 699-708
43. Boger R.H., Bode-Boger S.M., Brandes R.P., et al. Dietary l-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 96 (1997) 1282-1290
44. Mazzone A., Faggioli P., Cusa C., et al. Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia. Eur J Clin Invest 32 (2002) 882-888
45. Ylitalo P., Kaukinen S., Nurmi A.K., et al. Effects of a prostacyclin analog iloprost on kidney function, renin-angiotensin and kallikrein-kinin systems, prostanoids and catecholamines in man. Prostaglandins 29 (1985) 1063-1071
46. Alstaedt H., Berzewski B., Breddin H.K., et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 49 (1993) 573-578
47. Alt U., Leigh P.J., Wilkins A.J., et al. Desensitization of iloprost responsiveness in human platelets follows prolonged exposure to iloprost in vitro. Br J Clin Pharmacol 22 (1986) 118-119
48. Fisch A., Tobusch K., Veit K., et al. Prostacyclin receptor desensitization is a reversible phenomenon in humans platelets. Circulation 93 (1997) 756-760
49. Sydow K., Hornig B., Arakawa N., et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia:potential role of ADMA. Vasc Med 9 (2004) 93-101
50. GISAP Study Group. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). Int Angiol 13 (1994) 70-74